Catalyst Biosciences To Present at the Jefferies 2016 Complement Therapeutics Summit

SOUTH SAN FRANCISCO, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a leading biotechnology company focused on discovering and developing novel protease therapeutics for the treatment of serious medical conditions in the fields of hemostasis and anti-complement, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2016 Complement Therapeutics Summit on Tuesday, May 3, 2016 at 9:00 a.m. E.T. The conference is being held at the Jefferies Conference Center in New York City.

About Catalyst Biosciences Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit www.catalystbiosciences.com. 

Contacts:   
Investors:   
Fletcher Payne, CFO  
Catalyst Biosciences, Inc. 
650.871.0761   
[email protected] 

Media:   
Denise Powell
Red House Consulting, LLC
510.703.9491
[email protected]

You May Also Be Interested In

• Crescent Biopharma prices $125M public offering of shares and warrants
• Ceravindo Review [AU]: Is Ceravindo AI Trading Platform Worth It?
• Crescent Biopharma launches public offering of shares and warrants